iRhythm (IRTC) executive granted 10,034 RSUs in new equity award

Rhea-AI Filing Summary

Turakhia Minang reported acquisition or exercise transactions in this Form 4 filing.

iRhythm Holdings, Inc. reported that executive Minang Turakhia received an equity award in the form of Restricted Stock Units (RSUs) covering 10,034 shares of common stock at no cash cost on the grant date. Each RSU represents a right to receive one share if vesting conditions are met.

According to the vesting schedule, 25% of these RSUs vest on March 1, 2027, with the remaining RSUs vesting in equal portions on each one-year anniversary thereafter, as long as Turakhia continues as a service provider through each vesting date. Following this grant, Turakhia directly holds 58,933 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Turakhia Minang

(Last) (First) (Middle)

C/O IRHYTHM HOLDINGS, INC.

699 8TH ST #600

(Street)

SAN FRANCISCO CA 94103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
iRhythm Holdings, Inc. [ IRTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF MED/SCI OFCR EVP ADVTECH

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026	02/25/2026	A		10,034(1)	A	$0	58,933	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These securities are Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs vest on March 1, 2027 and each one-year anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date.

Remarks:

	/s/ Marc Rosenbaum, attorney-in-fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did iRhythm (IRTC) report for Minang Turakhia?

iRhythm reported that executive Minang Turakhia received a grant of 10,034 Restricted Stock Units. Each RSU represents a contingent right to one share of common stock, increasing his direct holdings to 58,933 shares after the award.

How many RSUs did Minang Turakhia receive from iRhythm (IRTC)?

Minang Turakhia received 10,034 Restricted Stock Units from iRhythm Holdings. These RSUs are equity awards with no cash paid per unit on the grant date, each convertible into one share of common stock upon vesting.

What is the vesting schedule for Minang Turakhia’s iRhythm (IRTC) RSUs?

25% of Minang Turakhia’s RSUs vest on March 1, 2027, with additional 25% tranches vesting on each one-year anniversary thereafter. Vesting requires that he continue as a service provider through each applicable vesting date.

Did Minang Turakhia buy or sell iRhythm (IRTC) shares in this Form 4?

This Form 4 reports an equity award acquisition, not an open-market buy or sell. Turakhia received 10,034 Restricted Stock Units as a grant with a reported price per share of $0.0000 on the transaction date.

How many iRhythm (IRTC) shares does Minang Turakhia hold after this RSU grant?

After the reported RSU grant, Minang Turakhia directly holds 58,933 shares of iRhythm common stock. This figure reflects his ownership following the award as disclosed in the Form 4 filing details.

What role does Minang Turakhia hold at iRhythm (IRTC)?

Minang Turakhia serves as Chief Medical and Scientific Officer and Executive Vice President of Advanced Technology at iRhythm. The Form 4 identifies him as an officer receiving a grant of Restricted Stock Units tied to his service.